Madrigal Pharma Revenue and Competitors

Location

#456

Growjo Ranking

Pharma

Industry

Estimated Revenue & Valuation

  • Madrigal Pharma's estimated annual revenue is currently $10.1M per year.(i)
  • Madrigal Pharma's estimated revenue per employee is $16,530
  • Madrigal Pharma's total funding is $38M.
  • Madrigal Pharma's current valuation is $1.3B. (January 2022)

Employee Data

  • Madrigal Pharma has 608 Employees.(i)
  • Madrigal Pharma grew their employee count by 34% last year.

Madrigal Pharma's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
CEOReveal Email/Phone
3
Chief Business OfficerReveal Email/Phone
4
Chief Counsel, Commercial & Sr. Associate General CounselReveal Email/Phone
5
Executive Assistant to the CFO and CBOReveal Email/Phone
6
Chief Legal Officer & Corporate SecretaryReveal Email/Phone
7
Chief Business OfficerReveal Email/Phone
8
Chief Business OfficerReveal Email/Phone
9
Chief Business OfficerReveal Email/Phone
10
CIOReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$43.2M1928%N/AN/A
#2
$81.8M3463%N/AN/A
#3
$11.7M580%N/AN/A
#4
$1011.8M5034-9%N/AN/A
#5
$44.8M178-3%N/AN/A
#6
$13.1M50-7%N/AN/A
#7
$16.5M8241%N/AN/A
#8
$17.3M68-4%N/AN/A
#9
$67.9M40230%N/AN/A
#10
$14.9M51-16%N/AN/A
Add Company

What Is Madrigal Pharma?

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy. For more information about Madrigal, please visit out website at https://www.madrigalpharma.com/ and follow us on Twitter at @MadrigalPharma.

keywords:N/A

$38M

Total Funding

608

Number of Employees

$10.1M

Revenue (est)

34%

Employee Growth %

$1.3B

Valuation

N/A

Accelerator

Madrigal Pharma News

2022-04-20 - Madrigal Pharmaceuticals to Announce First Quarter 2022 ...

CONSHOHOCKEN, Pa., April 28, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. MDGL+ Free Alerts. , a clinical-stage biopharmaceutical...

2022-04-20 - Zacks Investment Research Lowers Madrigal Pharmaceuticals ...

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic...

2022-04-13 - Madrigal: NASH Data In Q4 Is The Key

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a leading developer of liver disease medicines. In 2018, their biopsy-proven non-alcoholic...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$178.2M679N/AN/A
#2
$1700M761-2%N/A
#3
$285.6M88828%$40M
#4
$75M9197%N/A
#5
$619.2M1638N/AN/A